الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 215 |  |  |
| | | from | 215 | | |
Abstract
This study was conducted to evaluate a novel class of thiazole derivatives for their potential use in the treatment of cancer. 2-[2-(4-hydroxybenzylidene) hydrazinyl]. Thiazol [-4(5H)-one (4a) ,2- [2-(3-Bromo-4-hydroxy benzylidene) hydrazineyl]-Thiazol -4(5H) one (4b) ,2-[2(3-phenylazo-4-hydroxybenzlidene) hydrazine]-Thiazol -4(5H)-one (4c), 2-[2-(4-acetoxybenzylidene) hydrazine]-thiazole -4(5H)-one (5), 5-(3-methoxy-4-hydroxybenzylidene)2-2[2-(4-hydroxybenzylidene) hydrazineyl]-Thiazol-4-one (6).
Evaluation of the half maximal inhibitory concentration (IC50) of the newly synthesized thiazole compounds (4a-c) and 5 against two cancer cell lines (MCF-7 and HepG2) compared to Saturosporine (STU) as a reference standard anticancer drug.
Assessment of VEGFR-2 kinase inhibitory activity for the most active compounds (4a-c) and 5.
Cell cycle analysis for the most active compound.
Apoptosis and necrosis analysis for the most active compound.
Molecular docking study on protein receptor of [Aromatase, epidermal growth factor receptor (EGFR), Cyclin-dependent kinase2 (CDK2), and B-cell lymphoma2 (Bcl-2)].